Cabergoline is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Par Pharmaceutical, Inc.. The primary component is Cabergoline.
| Product ID | 49884-673_1c7edbc4-9a68-49b3-8ce6-67d25b6231d5 |
| NDC | 49884-673 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Cabergoline |
| Generic Name | Cabergoline |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2005-12-29 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA076310 |
| Labeler Name | Par Pharmaceutical, Inc. |
| Substance Name | CABERGOLINE |
| Active Ingredient Strength | 1 mg/1 |
| Pharm Classes | Ergolines [CS],Ergot Derivative [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2005-12-29 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | ANDA |
| Application Number | ANDA076310 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2005-12-29 |
| Ingredient | Strength |
|---|---|
| CABERGOLINE | .5 mg/1 |
| SPL SET ID: | ce51c53d-1cfa-4e5c-84d7-81024e10b4e8 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0093-5420 | Cabergoline | Cabergoline |
| 23155-823 | Cabergoline | Cabergoline |
| 49884-673 | Cabergoline | Cabergoline |
| 50090-3157 | Cabergoline | Cabergoline |
| 50090-3951 | Cabergoline | Cabergoline |
| 50090-5834 | Cabergoline | Cabergoline |
| 50742-118 | Cabergoline | Cabergoline |
| 59762-1005 | Cabergoline | cabergoline |
| 68071-4596 | Cabergoline | Cabergoline |
| 70518-2379 | Cabergoline | Cabergoline |